On Friday, ImmunityBio Inc (NASDAQ: IBRX) was -1.18% drop from the session before settling in for the closing price of $5.10. A 52-week range for IBRX has been $3.10 – $10.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 195.19% over the last five years. When this article was written, the company’s average yearly earnings per share was at 27.54%. With a float of $159.58 million, this company’s outstanding shares have now reached $670.87 million.
The firm has a total of 628 workers. Let’s measure their productivity. In terms of profitability, gross margin is -26.45%, operating margin of -4900.23%, and the pretax margin is -8018.24%.
ImmunityBio Inc (IBRX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward ImmunityBio Inc stocks. The insider ownership of ImmunityBio Inc is 77.10%, while institutional ownership is 9.88%.
ImmunityBio Inc (IBRX) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.38 earnings per share (EPS) during the time that was less than consensus figure (set at -0.18) by -0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.70% during the next five years compared to 1.17% growth over the previous five years of trading.
ImmunityBio Inc (NASDAQ: IBRX) Trading Performance Indicators
You can see what ImmunityBio Inc (IBRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 473.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.89, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.67 in one year’s time.
Technical Analysis of ImmunityBio Inc (IBRX)
Analysing the last 5-days average volume posted by the [ImmunityBio Inc, IBRX], we can find that recorded value of 2.57 million was lower than the volume posted last year of 4.92 million. As of the previous 9 days, the stock’s Stochastic %D was 64.73%. Additionally, its Average True Range was 0.44.
During the past 100 days, ImmunityBio Inc’s (IBRX) raw stochastic average was set at 43.07%, which indicates a significant increase from 42.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.87% in the past 14 days, which was lower than the 89.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.40, while its 200-day Moving Average is $5.29. Now, the first resistance to watch is $5.13. This is followed by the second major resistance level at $5.22. The third major resistance level sits at $5.27. If the price goes on to break the first support level at $4.98, it is likely to go to the next support level at $4.93. Now, if the price goes above the second support level, the third support stands at $4.84.
ImmunityBio Inc (NASDAQ: IBRX) Key Stats
There are 696,831K outstanding shares of the company, which has a market capitalization of 3.47 billion. As of now, sales total 620 K while income totals -583,200 K. Its latest quarter income was 6,110 K while its last quarter net income were -85,730 K.
